Lack of prophylactic effect of incadronate on skeletal lesions associated with implants of prostate cancer

To evaluate prophylactic effects of bisphosphonate (BP) on skeletal lesions induced by prostate cancer (CaP). Incadronate, a third-generation BP, was administered weekly for 4 weeks, with or without 4-week pre-administration, to rats whose calvaria had been inoculated with syngeneic CaP tissue. The...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2006, Vol.49 (1), p.176-182
Main Authors: HIKOSAKA, Atsuya, FUTAKUCHI, Mitsuru, OGISO, Tadashi, SUZUKI, Shugo, KOHRI, Kenjiro, SHIRAI, Tomoyuki
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Bone Density Conservation Agents - therapeutic use
Bone Neoplasms - prevention & control
Bone Neoplasms - secondary
Diphosphonates - therapeutic use
Gynecology. Andrology. Obstetrics
Male
Male genital diseases
Medical sciences
Neoplasm Transplantation
Nephrology. Urinary tract diseases
Prostatic Neoplasms - pathology
Rats
Rats, Inbred F344
Treatment Failure
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate prophylactic effects of bisphosphonate (BP) on skeletal lesions induced by prostate cancer (CaP). Incadronate, a third-generation BP, was administered weekly for 4 weeks, with or without 4-week pre-administration, to rats whose calvaria had been inoculated with syngeneic CaP tissue. The transplanted CaP grew up and caused bone resorption with osteoblastic changes regardless of incadronate treatment. Although decrease in bone resorption accompanied by reduced number of osteoclasts was shown by incadronate administration, pre-administration had no additional inhibitory effect on bone destruction and Ki-67 labeling indices of CaP cells were not altered. These results indicate that application of BP alone is not sufficient to prevent skeletal lesions due to CaP in patients with high risk of bone metastases although it is useful in inhibition of cancer-induced bone resorption with osteoblastic changes.
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2005.09.021